Optimize The Formulation For A Monoclonal Antibody

An emerging biotech company sought help developing a formulation for a monoclonal antibody. The company didn’t have in-house development expertise and wanted a partner capable of delivering an optimized formulation of buffers and excipients within an aggressive timeline and budget. As with all formulations, it was essential that the buffers and excipients selected ensured the stability of the drug substance, were compatible with each other, and met regulatory requirements. Explore how MilliporeSigma delivered an optimized formulation for this customer in three months.